Mar 02, 2015 6:30 am EST FDA Grants Breakthrough Therapy Designation to Epstein-Barr Virus (EBV) Targeted T-Cells for Treatment of EBV-Associated Lymphoproliferative Disease
Feb 26, 2015 4:05 pm EST Atara Biotherapeutics Announces Fourth Quarter and Full Year 2014 Operating Results
Feb 18, 2015 4:21 pm EST Atara Biotherapeutics Announces Closing of Underwritten Offering of Common Stock and Exercise of Underwriters' Option to Purchase Additional Shares
Nov 06, 2014 9:05 am EST Atara Biotherapeutics' Collaborating Investigators to Present Data at the American Society of Hematology Annual Meeting 2014
Oct 22, 2014 6:50 am EDT Atara Biotherapeutics Doses First Patient in Phase 1 Clinical Study of STM 434, an Activin Inhibitor